Skip to content
‹ Back to IndustriesSciences

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

Promoted content from Crown Bioscience on MarketScale.

By Crown Bioscience · · Preclinical ModelsOncology Drug DevelopmentOrthotopic ImplantationPatient-derived Xenografts
Share

Key takeaways

01

Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.

02

Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.

03

Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

At Crown Bioscience's San Diego site, some brain tumor studies start with the tumor implanted in the brain. According to the site, researchers there have been implanting brain tumors in the brain and then giving treatments directly in that setting. The tumor grows where it would in a patient, and the therapy is tested there, not in a more convenient spot under the skin.

That example sums up what the site offers oncology drug developers. A preclinical model should fit the therapy being tested, including its delivery route, the surgery it needs and the organ it targets. The question for a sponsor is whether a contract research partner can build that fit, and then capture the data needed to decide whether a program moves forward.

Fitting the model to the therapy, not the other way around

The San Diego team says bespoke work is what sets the site apart. New therapies do not always fit standard study designs. A treatment might need a specific surgical procedure, or it might depend on a device or instrument that is part of the therapy itself. The site says it can take on those requirements.

So if you have a particular surgery or a particular instrument that is part of the new therapy that you want to try, we have the skills to do that and adapt to the client's needs. — Christopher Dillon, Crown Bioscience San Diego

Custom procedures only help if there is a suitable tumor to use them on. The site offers cell line-derived xenografts covering a number of tumor indications and says it is adding more. The stated aim is flexibility: clients can pick a tumor model that matches both the treatment and the indication, instead of reshaping their question around whatever models happen to be on the shelf.

A cell line-derived xenograft (CDX) grows an established human cancer cell line in a host animal. A patient-derived xenograft (PDX) comes from a patient's tumor tissue. An orthotopic model places the tumor in the organ it originally came from, such as brain tumor cells implanted in the brain, instead of at a more accessible site.

The orthotopic work depends on many of the site's tumor models being tagged. According to the site, tagging lets researchers place tumors in their original organ and still follow tumor growth there. That matters most in organs where growth is hard to see directly, and the brain is the clearest case.

It is also why the brain tumor work, with implantation and treatment happening in the same place, is the site's lead example. It combines all three pieces: a custom procedure, a matched tumor model and a way to track what happens in the organ that counts.

Patient-derived models, including tumors that have already seen treatment

On patient-derived xenografts, the company says Crown has one of the largest PDX catalogs, covering a variety of indications, including some that are very rare to find. For a team working on an uncommon cancer, whether a relevant model exists at all can decide what gets studied before the clinic.

The site also points to PDX models developed after patients had already received treatment, which it says can help develop "the next wave of therapies." The logic is straightforward. For a program aimed at patients whose disease has progressed after earlier treatment, a model taken from a tumor already exposed to therapy may reflect that group better than a model from an untreated tumor.

Carrying samples from preclinical models to clinical testing

The San Diego site covers in vivo, in vitro and biomarker work, so clients can capture the full set of data they need to advance a project. The site describes itself as a translational biomarker hub: it processes samples from preclinical models and also tests clinical samples.

The biomarker approach is about purpose, not instrument count. "In the biomarker space, we really utilize each platform for its purpose," the site says. That includes flow cytometry, pathology and cytokine detection, each chosen for the scientific question the client is asking. The goal is to hand back insights, not just raw readouts.

Doing both kinds of work in one place could carry a practical benefit. If biomarker work on model samples and on clinical samples happens at the same site, a client may find it easier to connect what was measured in animals with what is later measured in patients.

Why custom work comes down to the people running it

Custom surgery, placing tumors in the organ they came from and dosing directly into the brain all depend on skilled hands. The San Diego site has a mix of PhD scientists and technical staff with bachelor's degrees, drawn from oncology and from fields outside it.

The clearest example of that range is a neuroscientist on staff who informs much of the site's work in brain oncology, including glioblastoma. That ties back to the opening. Implanting and treating tumors in the brain takes knowledge of the brain as well as knowledge of cancer.

The site says its quality rests on a very rigorous training program for research associates. The program is meant to make sure associates are highly skilled, act as stewards of animal welfare and produce the highest-quality data for clients. With nonstandard procedures, where there is no routine to fall back on, that training carries more of the load.

When a therapy depends on a specific route, device or tumor setting, ask a prospective partner to walk through how it tracks tumor growth in that organ and who on staff has done the procedure before. Those two answers say more about reproducibility than a model catalog does.

For drug developers looking for a US onshore testing partner, that is the test San Diego is putting itself up for: can it reproduce a therapy's real conditions reliably? Its answer rests on growing CDX offerings, tagged orthotopic models, post-treatment PDXs and staff trained to run procedures that don't come out of a standard playbook.

Crown Bioscience

Part of this channel

Crown Bioscience

News, updates, and expert insights from Crown Bioscience.

Visit the channel

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

CB
Crown Bioscience
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

SR-Tiget gene therapy families average six months in Milan and years of lab tests

SR-Tiget gene therapy families average six months in Milan and years of lab tests

Gene therapy at Milan’s SR-Tiget includes a family support programme that helps relatives manage months-long stays (often around six months) for treatment, while a regulated lab can track patient samples for up to 20 years. Follow-up visits can outnumber new treatments, adding to the long-term workload.

  • 01In 2025, SR-Tiget's family programme coordinated 133 follow-up visits against 17 new treatments. That gap keeps widening because each patient enters roughly 15 years of twice-yearly checkups.
  • 02At SR-Tiget, the average family spends six months in Milan, and the child's samples can keep reaching the lab for as long as twenty years.
  • 03Any gene therapy service has to answer one question: who tells the lab when a child's fever pushes a blood draw from morning to afternoon? In Milan, research nurses own that handoff.

Nov 16, 2026

Two photonic AI components reach outside testers—on limits

Two photonic AI components reach outside testers—on limits

Kopin is expanding microLED manufacturing in Westborough, Massachusetts, which could add up to 80 jobs over five years. Its microLEDs will go to military displays and to Neural I/o, an interconnect that sends AI data as light. In the same news round-up, Q.ANT and IONOS opened a photonic processor pilot where approved applicants can run their own workloads.

  • 01Two photonic approaches tied to AI’s power problem reached testable hardware this month: PsiQuantum’s 8×8 optical switch samples and Q.ANT’s second-generation processor via an IONOS bare-metal pilot in Germany.
  • 02PsiQuantum is sending samples of an 8×8 demonstration optical circuit switch to selected prospective customers, giving buyers hardware they can test even though commercial products and full specs are still pending.
  • 03Staffing may not keep up with demand: a 2023 Applied Optics study projected US demand for 42,000 new middle-skilled photonics workers by 2030, and expansions like Kopin's could draw from that same pool.

Nov 15, 2026

Lilly breaks ground on a $5B Virginia bioconjugate plant; first building expected in 2030

Lilly breaks ground on a $5B Virginia bioconjugate plant; first building expected in 2030

Lilly’s Goochland County site is designed to make APIs and finished medicines on one campus. Virginia Business reported the first building is expected to open in 2030.

  • 01Goochland’s pilot-scale training center is slated to open in 2028, two years before Lilly expects its first production building in 2030—signaling workforce readiness as the earliest milestone at Lilly’s first dedicated, fully integrated API and drug product facility for its bioconjugate platform and monoclonal antibody portfolio.
  • 02For anyone tracking new ADC supply, Goochland is a later story: Lilly expects to open the first building in 2030 and the second in 2031.

Nov 15, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Crown Bioscience

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512